SecurityUNLYF / Unilever, PLC (904784501)
Form 6-K Count212
Form CORRESP Count11
Form 424B5 Count9
Form FWP Count8

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Unilever, PLC


DateFormTitle
2018-09-05 424B5 UNLYF / Unilever, PLC 424B5 (Prospectus)
2018-09-04 424B5 UNLYF / Unilever, PLC 424B5 (Prospectus)
2018-03-20 424B5 UNLYF / Unilever, PLC 424B5 (Prospectus)
2018-03-19 424B5 UNLYF / Unilever, PLC 424B5 (Prospectus)
2017-03-02 6-K Unilever BATCH FILING (Current Report of Foreign Issuer)
2017-02-28 IRANNOTICE Unilever IRANNOTICE
2017-02-28 20-F Unilever 20-F
2017-02-22 6-K Unilever GUIDANCE UPDATE (Current Report of Foreign Issuer)
2017-02-22 6-K Unilever UNILEVER REVIEW (Current Report of Foreign Issuer)
2017-02-21 SC14D9C Unilever SC14D9C
2017-02-21 6-K Unilever JOINT STATEMENT FROM UNILEVER AND KRAFT HEINZ (Current Report of Foreign Issuer)
2017-02-17 SC14D9C Unilever SC14D9C
2017-02-17 6-K Unilever STATEMENT RE ANNOUNCEMENT BY KRAFT HEINZ COMPANY (Current Report of Foreign Issuer)
2017-02-10 6-K Unilever PUBLICATION OF FINAL TERMS: EUR1.2BN BONDS (Current Report of Foreign Issuer)
2017-02-08 6-K Unilever UNILEVER ISSUES EUR1.2BN BONDS ON EUROPEAN MARKETS (Current Report of Foreign Issuer)
2017-02-07 6-K Unilever BATCH FILING (Current Report of Foreign Issuer)
2017-02-02 6-K Unilever PUBLICATION OF FINAL TERMS: UNILEVER GBP350M BONDS (Current Report of Foreign Issuer)
2017-01-30 6-K Unilever UNILEVER ISSUES GBP350M BONDS ON STERLING MARKET (Current Report of Foreign Issuer)
2017-01-26 6-K Unilever PUBLICATION OF A PROSPECTUS (Current Report of Foreign Issuer)
2017-01-26 6-K Unilever FULL YEAR RESULTS 2016 (Current Report of Foreign Issuer)
2016-12-13 6-K Unilever BATCH FILING (Current Report of Foreign Issuer)
2016-11-08 6-K Unilever BATCH FILING (Current Report of Foreign Issuer)
2016-10-13 6-K Unilever 3RD QUARTER RESULTS (Current Report of Foreign Issuer)
2016-10-05 6-K Unilever BATCH FILING (Current Report of Foreign Issuer)
2016-09-06 6-K Unilever BATCH FILING (Current Report of Foreign Issuer)
2016-08-08 6-K Unilever BATCH FILING (Current Report of Foreign Issuer)
2016-07-28 6-K Unilever 6-K (Current Report of Foreign Issuer)
2016-07-27 6-K Unilever UNILEVER PRICES $1.25BN BOND ON THE U.S. MARKET (Current Report of Foreign Issuer)
2016-07-26 424B5 Unilever 424B5 (Prospectus)
2016-07-26 FWP Unilever FWP
2016-07-25 6-K Unilever 6-K (Current Report of Foreign Issuer)
2016-07-25 424B3 Unilever 424B3 (Prospectus)
2016-07-25 6-K Unilever 2ND QUARTER RESULTS 2016 (Current Report of Foreign Issuer)
2016-07-22 6-K Unilever 6-K (Current Report of Foreign Issuer)
2016-07-07 6-K Unilever BATCH FILING (Current Report of Foreign Issuer)
2016-05-31 6-K Unilever BATCH FILING (Current Report of Foreign Issuer)
2016-05-31 SD Unilever FORM SD
2016-05-04 6-K Unilever BATCH FILING (Current Report of Foreign Issuer)
2016-04-27 6-K Unilever PUBLICATION OF FINAL TERMS - EUR1.5BN BONDS (Current Report of Foreign Issuer)
2016-04-25 6-K Unilever UNILEVER ISSUES EUR1.5 BILLION BONDS (Current Report of Foreign Issuer)
2016-04-22 6-K Unilever PUBLICATION OF A PROSPECTUS (Current Report of Foreign Issuer)
2016-04-21 6-K Unilever RESULT OF 2016 AGM (Current Report of Foreign Issuer)
2016-04-14 6-K Unilever 1ST QUARTER RESULTS 2016 (Current Report of Foreign Issuer)
2016-04-04 6-K Unilever BATCH FILING (Current Report of Foreign Issuer)
2016-03-14 6-K Unilever 6-K (Current Report of Foreign Issuer)
2016-03-03 6-K Unilever BATCH FILING (Current Report of Foreign Issuer)
2016-02-24 6-K Unilever NOTIFICATION OF A CHANGE TO THE BOARDS (Current Report of Foreign Issuer)
2016-02-24 6-K Unilever PUBLICATION OF PROSPECTUS (Current Report of Foreign Issuer)
2016-02-23 IRANNOTICE Unilever Form IRANNOTICE
2016-02-23 6-K Unilever Form 6-K (Current Report of Foreign Issuer)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 904784501